GlassScriptPhysician profile
George Bolen
NPI 1093784555
$12,203.46
in general payments reported to CMS, 2019-2025
46 companies · $2,951 in 2025
The $2,951 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,457 · 2020: $166 · 2021: $84.41 · 2022: $1,261 · 2023: $2,348 · 2024: $2,937 · 2025: $2,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,186 · Education: $48.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,186.32 |
| Education | $48.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,144.03 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Janssen Biotech, INC. | $1,481.94 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,386.92 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $855.10 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $770.68 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $629.98 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $582.54 | 2023-2025 | Ibsrela |
| Pfizer INC. | $568.08 | 2019-2025 | |
| Genzyme Corporation | $426.50 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $378.00 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $368.44 | 2019-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $235.13 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $193.43 | 2023-2025 | Omvoh |
| Celltrion USA INC. | $192.92 | 2024-2025 | Vegzelma, Zymfentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.19 | 2023-2024 | Cyltezo |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Bolen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.